From building a comprehensive cancer center over the past 50 years to launching a new hub for oncology innovation and technology transfer: a major milestone has been reached.
Last Friday, the Montpellier Cancer Institute introduced the Innovation & Technology Cancer Center (CTIO) to our academic and institutional ecosystem.
Over five decades, the Montpellier Cancer Institute has built a unique 360° cancer campus — bringing together a major university hospital, the IRCM world-class research center, and the Epidaure cancer prevention unit. For the past 10 years, the site has also held the SIRIC label from the French National Cancer Institute, a recognition of the collaborative excellence in cancer research uniting teams from CNRS, CHU, Montpellier University, INSERM, ICM, and IRCM.
CTIO now marks a new chapter: scaling up groundbreaking research in cancer metabolism and immunotherapy, with one key objective: translating validated research markers directly into clinical care.
Looking ahead to 2030, a major computational department will emerge within CTIO. It will bring together exceptional teams in computational imaging and virtual biopsies, systems biology, bioinformatics and biostatistics, antibody modeling, genome and epigenome modeling, and large-scale clinical data integration. We believe that unlocking the full potential of our data and harnessing AI will be central to advancing both cancer research and care in the coming decade.
CTIO will provide a platform for oncology research spinoffs, helping them reach the market with strong support from our partners.
This ambitious move strengthens our MedVallee ecosystem and paves the wayfor cancer innovation in Montpellier.
